Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGCG | Q16739 | 6/20 | 0.83 |
| ▸ | RORC | P51449 | 2/20 | 0.49 |
| ▸ | MLYCD | O95822 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.40 |
| ▸ | AXL | P30530 | 2/20 | 0.40 |
| ▸ | MET | P08581 | 1/20 | 0.40 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.40 |
| ▸ | MERTK | Q12866 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29907685 | 0.91 | UGCG (0.69) | UGCGRORCNPSR1AXLMET | |
| SCHEMBL29907592 | 0.91 | UGCG (1.00) | UGCGNPSR1S1PR1AXLMET | |
| SCHEMBL29907476 | 0.90 | UGCG (0.81) | UGCGNPSR1AXLMETTYRO3 | |
| SCHEMBL24464224 | 0.87 | UGCG (0.81) | UGCGNPSR1S1PR1AXLNPC1 | |
| SCHEMBL29907485 | 0.87 | UGCG (0.78) | UGCGNPC1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL29907364 | 0.85 | UGCG (0.80) | UGCGNPSR1AXLMETNPC1 | |
| SCHEMBL29907361 | 0.85 | UGCG (0.89) | UGCGAXLMETTYRO3MERTK | |
| SCHEMBL24464290 | 0.85 | UGCG (0.89) | UGCGAXLMETTYRO3MERTK | |
| SCHEMBL29907405 | 0.84 | UGCG (0.65) | UGCGRORCAXLMETTYRO3 | |
| SCHEMBL29907554 | 0.84 | UGCG (0.72) | UGCGNPSR1S1PR1AXLMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220289679-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220289679-A1 | HETEROCYCLIC COMPOUND | GBA1, GBA2, GALC | UGCG 10/4885RORC 4397/4885MLYCD 1664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.